We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

6,600
Open access books available

177,000
International authors and editors

195M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Interactions Between Total Plasma Homocysteine, Oxidized LDL Levels, Thiolactonase Activities and Dietary Habits in Tunisian Diabetic Patients

Nadia Koubaa et al.*

Bichemistry laboratory, UR“Human Nutrition & Metabolic Disorders” Faculty of Medicine Monastir, Tunisia

1. Introduction

Cardiovascular disease (CVD) is the predominant cause for morbidity and mortality in diabetes mellitus (DM). Patients with diabetes mellitus have two to three times the incidence of atherosclerotic disease compared to the general population (Kannel & McGee, 1979). Several etiologic factors increase susceptibility to CVD in DM including insulin resistance, dyslipidemia, endothelial dysfunction, prothrombosis, and increased protein glycation (Baynes & Thorpe, 1999).

Plasma homocysteine levels are elevated in patients with diabetes, particularly in patients with type 2 diabetes as well as in individuals in prediabetic states who exhibit insulin resistance. Homocysteine (Hcy) is a non-essential amino acid that is produced from demethylation of methionine. Hcy can be remethylated into methionine by means of vitamin B12-dependent methionine synthase and 5-methyltetrahydrofolate as a methyl donor. Hcy can be also catabolized into cysteine (the transsulfuration pathway) via cystathionine beta synthase and cystathioninase, both enzymes being vitamin B6-dependent. A third way to remove Hcy is conversion to S-adenosylhomocysteine (SAH). The last reaction is mediated by SAH-hydrolase and favors the SAH formation in case of increased Hcy concentrations. S-Adenosyl methionine (SAM) is a universal methyl donor that is formed from methionine and converted into SAH after donating its methyl group. SAH is a potent inhibitor of most known methyltransferases (Kloor & Osswald, 2004).

Among the main determinants of Hcy levels in non-diabetic subjects are age, sex, renal function, several diseases, drugs, coffee and chronic alcohol consumption, smoking and physical inactivity (Refsum et al., 2006). Genetic factors and nutritional deficiencies of folate...
or of the vitamin cofactors (vitamins B12, B6 and B2) involved in Hcy metabolism may also promote hyperhomocysteinemia. Besides other genetic defects, a thermolabile variant of Methylene Tetrahydrofolate Reductase (MTHFR), a key enzyme of the remethylation pathway, has been described (Frosst et al., 1995). It has been shown that this gene variation was associated with increased levels of homocysteine; Heterozygotes carrying MTHFR thermolabile variant have a reduced enzyme activity (down to 65% of normal levels), while homozygotes have only 30% of normal activity (Frosst et al., 1995). In type 2 diabetic patients, levels of homocysteine are influenced by their insulin concentrations, therapy with insulin, and medications such as metformin and glitazones that can either raise or lower homocysteine levels.

Epidemiological studies have identified elevated homocysteine (hyperhomocysteinaemia) as an independent risk factor for cardiovascular disease. Elevated levels of homocysteine (Hcy) above 12.1 μmol/L have been shown to double the risk of pathophysiological conditions such as atherosclerosis, myocardial infarction, cerebral or peripheral vascular diseases (Castro et al., 2006). Mean plasma total Hcy (tHcy) was found to be significantly higher both in male and female patients with CAD compared to controls with angiographically normal coronary arteries (Kang et al., 1992). An increase in plasma Hcy of only 12% greater than the upper limit of normal was shown to be associated with an increase by 3.4-fold in the risk of myocardial infarction (Stampfer et al., 1992). After adjusting for possible confounders, Arnsen et al. (Arnsen et al., 1995) found a relative risk for coronary heart disease of 1.32 for an increase in serum Hcy of 4 μmol/l. A meta-analysis of 27 studies relating Hcy to coronary, cerebrovascular and peripheral arterial vascular diseases showed a very strong relationship between these diseases and tHcy (Boushey et al., 1995).

Elevated Hcy may also contribute to progressive atherosclerosis by several mechanisms, including arterial endothelial function impairment, oxidative stress induction, and the promotion of inflammation and thrombosis (Castro et al., 2006; Wald et al., 2002; 2004; Jakubowski, 2006). A unifying hypothesis for the mechanism of Hcy-mediated vascular injury has not yet been established. One frequently described mechanism involves oxidative damage, as Hcy can undergo autoxidation in the plasma or intracellularly, to form various reactive oxygen species (Welch & Loscalzo, 1998). The potent reactive superoxide and hydrogen peroxides, which are produced during this process, are mainly responsible for the vascular toxicity of homocysteine via the formation of oxidized low density lipoprotein (ox-LDL). The oxidation of LDL in the artery wall is believed to be the primary event leading to the initiation and progression of atherosclerosis (Steinberg & Witztum, 2002; Parthasarathy et al., 1998). Hcy has also been shown to decrease the activity (Nishio & Watanabe, 1997) as well as the expression of the antioxidant enzyme glutathione peroxidase (Upchurch et al., 1997). Creation of a prothrombotic environment by the action of Hcy on various factors involved in coagulation has also been proposed (Ratnoff, 1968; Fryer et al., 1993; Nishinaga et al., 1993). The reaction of Hcy with nitric oxide (NO) acts to prevent oxidative damage caused by Hcy but at the same time reduces the bioavailability of NO by trapping it intracellularly as a nitrosothiol (Jacobsen, 2001). Hcy is also a potent mitogen for vascular smooth-muscle cells (Harker et al., 1983; Tsai et al., 1994). Aggregates formed by the combination of Hcy thiolactone, a cyclic product of Hcy, with LDL (low-density lipoprotein) were shown to be taken up by intimal macrophages and be incorporated into atheromatous plaques (Naruszewicz et al., 1994). Hcy thiolactone is also incorporated into cellular and secretory proteins through lysine homocysteinylation, leading to the dysfunction of the proteins (Jakubowski, 1997). The high density lipoprotein (HDL) particle(s) is known to prevent the
formation of ox-LDL by means of the HDL-associated enzyme paraoxonase (PON); its antioxidant properties prevent the accumulation of lipid peroxides on LDL (Shih et al., 1998). Paraoxonase is a multifunctional antioxidant enzyme that not only can destroy Ox-LDL but also can detoxify the homocysteine metabolite, homocysteine thiolactone (Jakubowski H, 1997). In fact, human paraoxonase possesses a thiolactonase (HTase) activity, hydrolyzing Hcy thiolactone to Hcy (Jakubowski, 1999). Hcy thiolactone is likely a natural substrate of HTase/paraoxonase (Jakubowski, 2004) a product of the PON1 gene (Furlong et al., 1988).

The effect of diet on human health has already been underlined in many studies. During the past years population-based surveys and large-scale clinical trials have provided scientific evidence that diets, and especially those rich in fruits, vegetables, legumes, whole grains, fish and low-fat dairy products, are associated with lower incidence of various chronic diseases, including diabetes, cardiovascular disease and cancer (Ascherio et al., 1992; Appel et al., 1997; Price & Fowkes, 1997; Koubaa et al., 2007). Diet has also an important role among the factors affecting homocysteine levels. Mediterranean diet, with a high proportion of bioactive compounds (vitamins, polyphenols and flavonoids) proved its efficiency in lowering plasma homocysteine levels and reducing the incidence of cardiovascular disease. The aim of the current study was to investigate whether elevated Hcy levels are associated with oxidation of LDL, and thiolactonase activity in type 2 diabetic patients, and further explore the contribution of various dietary components to prevent diabetes vascular complications and atherosclerosis progression.

2. Patients and methods

2.1 Study population

110 diabetic patients (54.2 ± 10.7 years) and 120 non diabetic healthy controls (44 ± 12.3 years) with available metabolic and life style informations were involved in this study. These patients did not receive any antioxidant drugs and none used hormonal replacement therapy. The following data were obtained: age, sex, weight. Height hip and waist circumference were measured using a standard scale. The study was approved by our hospital ethical committee, and informed consent was obtained from all patients before their enrolment. Major requirements for enrolment in all the groups were: absence of infectious or acute/chronic inflammatory diseases, known malignancy, absence of acute/chronic renal failure, or hepatic failure.

2.2 Laboratory procedures

Validated laboratory procedures were used as described previously (Koubaa et al., 2008). Plasmatic total homocysteine (free and protein bound) was determined by a validated highly sensitive and accurate capillary gas chromatography mass spectrometry method (GC-MS) using a stable isotope as internal standard. Thiolactonase (HTLase) activity was estimated by a commercially available kit assay (Alfresa Auto HTLase; Alfresa Pharma Corporation, Japan). This method utilizes gamma-thiobutyrolactone as substrate and Ellman’s procedure to monitor the accumulation of free sulphydryl groups via coupling with 5,5-dithiobis(2-nitrobenzoicacid).

Lipids and lipoproteins (Triglycerides; TG, total cholesterol: TC mmol/l, High density lipoprotein- cholesterol HDL mmol/l, Low density lipoproteins cholesterol: LDL mmol/l, triglycerides: TG mmol/l) concentrations were determined by enzymatic way. Apolipoproteins Apo A1 and Apo B were determined by an immunoturbidimetric method (Randox, Antrim, UK). Oxidized LDL levels (ox-LDL) were
measured by a sandwich ELISA method using a commercial kit (ox-LDL ELISA Kit; immunodiagnostic Bensheim, Germany). The dietary habits of the diabetic patients were evaluated. Food intakes were estimated by two dieticians using one-week diet recalls. Subjects were asked about their daily diet over a week period: they were asked about amounts, frequencies and variations in consumption. Nutrient intakes were calculated using the software Nutritionist IV computer analysis (Nutritionist IV Computer Analysis Program, 1994, Version 3.1, N2 Computing, Hearst Corp. Salem, OR).

2.3 Statistical analysis
Statistical analyses were assessed using the Statistical Package for Social Sciences (SPSS Inc., Chicago). Data are presented as median (25th to 75th interquartile range I.R) for several variables that were not normally distributed and comparison between the 2 groups was performed with the Mann–Whitney U test. The normally distributed values were expressed as means with standard deviations and group differences analyzed using the Student’s t test. To test the association between the variables, either Pearson’s correlations or Spearman’s correlation rank (R) were used. Values of \( p < 0.05 \) were considered to be statistically significant.

3. Results

3.1 Participants characteristics
The clinical and biochemical features of the healthy and diabetic patients are listed in table 1. Diabetic patients exhibited significantly higher mean values of systolic and diastolic blood pressure, cholesterol, triglycerides, creatinine and urea, while HDL-C and ApoA1 were not significantly different.

|                  | Healthy controls (n=120) | Diabetics (n=110) | p   |
|------------------|-------------------------|------------------|-----|
| Age (years)      | 44 ± 12.3               | 54.2 ± 10.7      | 0.00|
| BMI (kg/m\(^2\)) | 26.7 ± 4.0              | 28.9 ± 5.7       | 0.00|
| WHR              | 0.91 ± 0.08             | 0.96 ± 0.07      | 0.01|
| SBP (mm Hg)      | 12.1 ± 1.2              | 14.6 ± 9         | 0.033|
| DBP (mm Hg)      | 7.06 ± 0.9              | 7.8 ± 1.2        | 0.00|
| Glucose (mmol/L) | 5.23 ± 1                | 10.98 ± 4.2      | 0.00|
| Creatinine (µmol/L) | 88.2 ± 19.3            | 85.8 ± 39.2      | 0.58|
| Urea (mmol/L)    | 4.9 ± 1.6               | 6.8 ± 2.7        | 0.00|
| Cholesterol (mmol/L) | 4.4 ± 1.2              | 4.9 ± 1.4        | 0.00|
| Triglycerides (mmol/L) | 1.3 ± 0.8              | 2.1 ± 1.2        | 0.00|
| HDL-C (mmol/L)   | 1.01 ± 0.28             | 1.01 ± 0.28      | 0.97|
| LDL-C (mmol/L)   | 2.7 ± 1.1               | 3 ± 1.5          | 0.08|
| ApoA1 (g/L)      | 1.29 ± 0.27             | 1.39 ± 0.43      | 0.1 |
| ApoB (g/L)       | 0.83 ± 0.28             | 1.39 ± 0.43      | 0.03|
| tHcy (µmol/L)\(^c\) | 11.76 (10.7 – 12.81)    | 12.87 (9.7 – 17.5) | 0.01|
| ox-LDL (ng/mL)   | 78.4 ± 23.7             | 139.6 ± 52.2     | 0.00|
| HTase (U/L)      | 569.9 ± 254             | 442.8 ± 211.8    | 0.01|

SBP, DBP: systolic and diastolic blood pressure
Values are expressed as mean ± SD
\(^*: p<0.05; **: p<0.001\)
\(^c\): expressed as median (I.R) and tested with the Mann Whitney’s U test

Table 1. Clinical and biochemical features of the healthy Tunisians and diabetic patients
Interactions Between Total Plasma Homocysteine, Oxidized LDL Levels, Thiolactonase Activities and Dietary Habits in Tunisian Diabetic Patients

pressure (SBP and DBP), Waist to hip Ratio (WHR) and body mass index (BMI). As far as the biochemical features of the patients and healthy groups were examined, the diabetics exhibited significantly elevated urea levels as compared to healthy subjects (4.9 ± 1.6 vs. 6.8 ± 2.7, p= 0.00). Serum triglycerides and total cholesterol levels were also significantly higher in these patients (p = 0.00 and p=0.003 respectively) associated to significantly higher Apo B levels. In addition we found a significant increase in plasma homocysteine levels (11.76 (10.7 – 12.81) vs. 12.87 (9.7 – 17.5) µmol/l; P=0.01) associated with lower Thiolactonase activities (442.8 ± 211.8 vs. 569.9 ± 254 U/ml, P=0.01) and higher oxidized LDL levels (139.6 ± 52.2 vs. 78.4 ± 23.7 ng/ml p = 0.00) as compared to healthy subjects (table 1).

3.2 Correlations analysis
The correlations between plasma homocysteine levels, thiolactonase activities and oxidized LDL levels were then evaluated with some clinical and biochemical features in the diabetic patient’s group. As expected, thiolactonase activities were associated negatively with tHcy levels (r= -0.554, p= 0.00), total cholesterol (r= -0.345, p< 0.05), LDL levels (r= -0.358, p< 0.05). Oxidized LDL levels were in opposite positively correlated with total cholesterol (r= 0.313, p< 0.05), creatinine levels (r= 0.353, p< 0.05) and BMI (r= 0.315, p<0.05).

|            | tHcy     | HTase    | ox-LDL | BMI    | TC     | LDL-C | creatinine |
|------------|----------|----------|---------|--------|--------|--------|------------|
| tHcy       | 1.00     | -0.554** | -0.060  | .080   | .068   | .036   | .039       |
| HTase      | -0.554** | 1.000    | -0.198  | -.115  | -.345* | -.358* | -.013      |
| ox-LDL     | -.060    | -0.198   | 1.00    | .315*  | .313*  | .260   | .353*      |

*: p<0.05; **: p<0.001
£: tested with the Spearman’s test of correlation

Table 2. Correlations between thiolactonase activity, plasma total homocysteine and oxidized LDL levels, with some clinical and biochemical features in the diabetic patients

3.3 Dietary surveys
As far as the dietary habits were considered we established that in the diabetic patients, the relative percentages of protein intakes per total calories were higher (12.4 ± 1.9 vs. 13.7 ± 3.8 %, p< 0.05) but the relative percentages of carbohydrate intakes per total calories were lower (50.7 ± 7.7 vs. 56.8 ± 5.4 %, p<0.001). The diabetic patient’s diet was significantly richer in fats (30.8 ± 5.9 vs. 35.9 ± 7.5 %, p<0.00). They were consuming higher polyunsaturated fatty acids (14.2 ± 10.4 vs. 21.6 ± 17.4 %, p<0.00) but significantly lower monounsaturated and saturated fatty acids.

Finally, as the correlations with the nutrients and were examined we noticed that tHcy was positively correlated with intakes of protein (r = 0.267, p<0.00), saturated fatty acids (r = 0.334, p<0.00) and cholesterol (r = 0.265, p<0.05) as illustrated in table 4. Plasma homocysteine levels were also correlated with dietary sodium and zinc intakes. Thiolactonase activity was negatively associated with proteins (r = -0.345, p<0.05) and cholesterol intakes (r = -0.313, p<0.05). Ox LDL levels were positively correlated with lipid intakes in the diabetic patients (r = 0.324, p<0.05).
Role of the Adipocyte in Development of Type 2 Diabetes

|                      | Healthy subjects | Diabetics |
|----------------------|------------------|-----------|
| Proteins (%)         | 12.4 ± 1.9       | 13.7 ± 3.8* |
| A/V                  | 1.06 ± 0.27      | 1.1 ± 0.48 |
| Carbohydrates (%)    | 56.8 ± 5.4       | 50.7 ± 7.7** |
| Fats (%)             | 30.8 ± 5.9       | 35.9 ± 7.5 ** |
| SFA                  | 23.2 ± 9.4       | 16.8 ± 8.1 ** |
| MUFA                 | 46.9 ± 9.4       | 32.9 ± 14.8 ** |
| PUFA                 | 14.2 ± 10.4      | 21.6 ± 17.4* |
| Cholesterol (mg)     | 188.2 ± 154      | 507.4 ± 206 |
| Calcium (mg)         | 483.1 ± 154.3    | 507.4 ± 206 |
| Vitamin B1 (mg)      | 0.49 ± 0.12      | 0.48 ± 0.16 |
| Fiber (g)            | 16.3 ± 4.7       | 34.2 ± 15.5 |
| Vitamin C (mg)       | 77.5 ± 30.4      | 82.7 ± 50.5 |
| Vitamin E (mg)       | 7.1 ± 3.4        | 9.9 ± 10   |
| Folates (µg)         | 134.4 ± 54.9     | 157.4 ± 71.2 |

A/V: percentage of Animal protein/percentage of vegetal protein; SFA: Saturated fatty acids, MUFA: Monounsaturated fatty acids, PUFA: Polyunsaturated fatty acids and.

*: p<0.05; **: p<0.001

Table 3. Daily nutrient intakes of the healthy and diabetic patients

|                      | tHcy £   | HTase | ox-LDL |
|----------------------|---------|-------|--------|
| Proteins (%)         | .267**  | -.345*| -.091  |
| Fats (%)             | -.138   | .226  | .324*  |
| SFA                  | .334**  | -.012 | -.012  |
| Cholesterol (%)      | .265*   | -.313*| -.028  |
| Sodium               | .324*   | -.234 | -.260  |
| Zinc                 | .272*   | .211  |        |

*: p<0.05; **: p<0.001
£: tested with the Spearman’s test of correlation

Table 4. Correlations between thiolactonase activity, plasma total homocysteine and oxidized LDL levels with selected nutrients in the diabetic patients

4. Discussion

Diabetic subjects constitute a patient population at high risk for cardiovascular disease, due to the influence of a clustering of risk factors. Plasma tHcy is considered as an emerging independent nontraditional risk factor for atherosclerotic vascular disease, which may enhance the effect of the traditional risk factors (Graham, 1997; Hackam & Anand, 2003). It is also a strong predictor of cardiovascular and all-cause mortality (Bostom et al., 1999). Therefore, it is important to know if dietary habits and lifestyle can affect plasma tHcy levels in this population, and eventually select the patients who would be at a higher risk for developing such complications. In the present study, tHcy levels
were higher in the diabetic patient’s group. Plasma tHcy levels have been studied extensively in diabetic, as well as in non-diabetic subjects. A number of studies did not find any differences in plasma tHcy values between diabetic and control subjects (Salarde et al., 2000; Lanfredini et al., 1998; Pavia et al. 2000, Diakoumopoulou et al., 2005). Some investigators demonstrated lower levels of tHcy in diabetics versus controls (Matteucci et al., 2002; Wollesen et al., 1999; Salardi et al., 2000). However, our findings are in accordance with other reports where tHcy were higher in the diabetic patients (Passaro et al., 2000; Yeromenko et al., 2000). Furthermore, homocysteine increases the production of ox-LDL and enhances their uptake by macrophages leading to the formation of foam cells that play a crucial role in atherosclerotic lesions (Tsai et al.,). Ox-LDL are considered as biochemical markers of coronary artery disease (Toshima et al., 2000 ; Holvoet et al, 2001). Accordingly, we found high levels of ox-LDL in diabetic patients exhibiting the highest levels of tHcy, which confirms the oxidative effect of homocysteine in the type 2 DM patients. Every 5 μM/L increase in the Hcy concentration increases the risk of CVD by 50%, and TC levels by 20 mg/dL. (Castro et al., 2006; Wald et al., 2002; Nygard et al., 1998; Genset et al., 1990). The mechanisms possibly responsible for causing endothelial dysfunction include changes in LDL, and Ox-LDL. The oxidation of LDL is increased by the combination of thiolactone and apo B’s free lysyl epsilon amino residue (Rocchi et al., 2007; Mansoor et al., 1993, 2000). When LDL is reacted with Hcythiolactone in methionine, which is an explicit initiator of arteriosclerosis, LDL-binding thiol is increased by 250 nM per mg of LDL protein ( Ferguson et al. 1999). The free amino- or thiol-adducted LDL causes aggregation, and increases LDL uptake in macrophages and atheroma production by lipids (Perna et al., 2003). Another mechanism by which Hcy may cause LDL oxidation is a possible deformation of LDL through Hcy autoxidation, which causes the oxidation of side chains of LDL such as fatty acids or apo B-100 (Young & Woodside, 2000). Both Hcy and Ox-LDL could participate in thrombosis by increasing VCAM-1 and ICAM-1, caused by endothelial cell activation due to fibrinogen-platelet GPIIb-IIIa formation. Ox-LDL affects both initial and progressive stages of arteriosclerosis (Jakubowski, 2000; Dardik et al., 2000; Vadachkoria et al., 2004; Erl et al., 2000). On the other hand, circulating Hcy reduces NO-induced detoxification, vasodilation, and endothelial function (Rocchi et al., 2007). NO participates in a metabolic pathway (S-nitroso-HCY) that is able to protect against Hcy-induced endothelial oxidative damage. Paraoxonase plays also a key role in reducing Hcy endothelial damages. In our previous results, we found a decline in endogenous antioxidant defense system capability in type 2 DM patients indicating their high oxidative stress (Smaoui et al., 2006). Antioxidant status of enzymes in DM patients is controversial. Several authors have reported that lipid peroxides level increases in type 2 DM patients (Mooradian, 1991); on the other hand, other studies found no significant increase in these patients (Velazquez et al., 1991). Among the numerous antioxidant enzymes, we focused in the present study on the thiolactonase activities which were decreased in the diabetic patients. Most studies evaluated the paraoxonase activity in Type I and Type II diabetic patients and found a decreased activity in these patients (Boemi et al., 2001; Kordonouri et al., 2001; Letellier et al., 2002; Mackness B et al., 1998; 2002; Agachan et al., 2004). Paraoxonase is a multifunctional antioxidant enzyme that not only can detoxify paraoxon, destroy oxidized low-density lipoprotein (ox-LDL) but also can hydrolyze homocysteine thiolactone.
The mechanism by which PON1 is reduced in diabetes is poorly understood, but may be associated with an increase in blood glucose concentration. Glycation can both inactivate PON1 and increase lipid peroxidation in HDL (Hedrick et al., 2000). Glycated HDL also has a reduced ability to protect against oxidation (Ferretti et al., 2001). PON1 activity and concentration were decreased also in studies of healthy subjects with elevated fasting glucose levels (Leviev et al., 2001; Kordonouri et al., 2001). Our finding showed a negative association between HTase activities, tHcy levels and oxidized LDL levels. These levels were associated with higher triglycerides, total cholesterol and also higher Apo B levels. Apo B is superior to cholesterol and triglycerides as a coronary syndrome risk factor due to the heterogeneity of lipoprotein particle composition. In fact, plasma Apo B concentrations reflect the number of atherogenic lipoprotein particles including LDL, and chylomicron remnants which contain variable amounts of triglycerides and cholesterol, but each of these particles contain 1 molecule of Apo B as structural protein. Then, higher levels of Apo B found in the diabetic patients reflects their higher risk for developing cardiovascular diseases (Sniderman et al., 1997).

The SBP and DBP were also increased in the diabetic patients. The association between homocysteine and chronic complications of diabetes mellitus could be explained by different mechanisms; direct toxic effect on vascular endothelial and indirect effect on the normal methylation in endothelial cells (Weir & Molloy, 2000). Direct toxic effect of homocysteine could be mediated by damage to vascular endothelial cells, resulting in vascular events, such as microvascular disease. In the study of Fiorina et al. (Fiorina et al., 1998), Caucasian patients with elevated tHcy levels had significantly higher diastolic pressure and mean arterial pressure. These results are similar to our data. Other populations (Indians) have shown correlation between homocysteine concentrations and body weight (Das et al., 1999). Our results did not show correlations among tHcy and different anthropometric parameters (body mass index, waist to hip ratio). Nevertheless, a positive correlation between ox-LDL levels and BMI was established in the diabetic patients. There was also a positive association between ox-LDL levels and creatinine levels in the diabetic patients. No correlation was found between creatinine and tHcy levels. Most studies have been able to show a positive correlation between plasma Hcy and plasma creatinine levels, suggesting the importance of the kidney in the regulation of plasma Hcy. Renal function in Type 2 diabetes appears to change with the progress of the disease: hyperfiltration in the early stages and progressive deterioration with the progression of diabetes. Diabetes therefore provides an interesting situation with changes in kidney functions being superimposed on the already existing changes in the metabolic milieu. Moreover, we found a negative association between HTase activities tHcy levels and the levels of total cholesterol and ox-LDL. In fact, in certain diseases e.g. diabetes where HDL size is reduced, secretion of PON1 is affected due to the fact that PON1 tends to bind to larger sized species of HDL both in vivo (Blatter et al.,1993) and in vitro (Deakin et al., 2002). In addition, in vitro studies demonstrated that PON1 was inactivated by oxidized lipids and oxidized LDL (Aviram et al., 1999). PON1 is highly susceptible to inactivation by oxidation. In vitro, PON1 activity is protected by the antioxidant polyphenols quercetin and glabridin (Aviram et al., 1999), suggesting that dietary antioxidants may play a similar role in vivo. Studies have shown that consumption of pomegranate juice, rich in polyphenols and other antioxidants, can raise PON1 activity up to 20% in both humans and apoE knockout mice (Kaplan et al., 2001). Polyphenols extracted from red wine also increase PON1 activity in mice (Hayek et al., 2001).
Recent work from Gouédard et al. (Gouédard et al., 2004) provides evidence that dietary polyphenols can influence PON1 gene expression. Clinical trials of the antioxidant vitamins C and E have, to date, been unsuccessful in showing a link between vitamin intake and CHD risk. Likewise, their effect, if any, on PON1 activity is not clear. Jarvik et al. (Jarvik et al., 2002) found that PON1 activity correlated positively with the quantity of vitamins C and E in the diet; however, another study in which vitamin E was given to volunteers showed no change in PON1 activity (Arrol et al., 2000). In contrast, oleic acid from olive oil is associated with increased activity (Tomas et al., 2001; Wallace et al., 2001). Meals rich in used cooking fat, which contains a high content of oxidized lipids, were followed by a significant fall in PON1 activity when fed to healthy men (Sutherland et al., 1999). These correlations were not confirmed by our results. The thiolactonase activities were correlated negatively with protein and cholesterol intakes. Plasma homocysteine levels were in opposite positively correlated to protein intakes, the relative percentage of fats and saturated fatty acids in diet and sodium intakes. Accordingly, in the Hordaland study that included 5917 subjects, a higher intake of saturated fatty acids was positively associated with higher concentrations of plasma Hcy. Concentrations of Hcy were higher (by 8.8%) in the group with the highest intakes of saturated fatty acids compared to that with the lowest intake (Berstad et al., 2007). Food-based feeding trials have shown a reduction in blood Hcy in subjects who consume fortified cereals or whole grains in combination with fruits, vegetables and low fat dairy products (Lutsey et al., 2006; Appel et al., 2000). Several carefully studied populations in Mediterranean countries and in some areas in Asia, where traditional diets consist largely of foods of plant origin, exhibit low rates of many chronic diseases and long life expectancies. Many case-control and prospective studies have provided further evidence that high consumption of plant foods confers numerous health benefits. Although the mechanisms are not fully understood, carotenoids, folic acid, and fiber, all of which are abundant in the Mediterranean diet, appear to play important roles in the prevention of coronary artery disease (Kushi et al., 1995).

5. Conclusion

In conclusion, Hcy and thiolactonase activities and oxidized levels are interrelated in type 2 diabetic patients and are responsible, at least partly, of the vascular complications. Strong evidence suggested that excess of plasma homocysteine disturb lipid metabolism via the oxidation of LDL particle and its aggregation, and enhancing atherosclerosis progression. Another line of evidence suggested that thiolactonase activity is affect in diabetics partly by a glycation process that accentuates the endothelial damages of homocysteine. A very interesting aspect to be tested in future studies is the beneficial effect of certain nutriments on lipid parameters and plasma homocysteine levels. Future long-term studies on larger populations are needed for determining the exact role of homocysteine in the development of diabetes vascular complications and the metabolic ways of prevention.

6. Acknowledgment

This work was supported by a grant from the “Ministère de l'Enseignement Supérieur, de la Recherche Scientifique et de la Technologie” UR “Nutrition Humaine et Désordres Métaboliques” UR03ES08 and USCR-Spectrométrie de masse. We would like to thank
Alfresa Pharma Corporation, Japan for their assistance. We are also thankful to all the clinicians for their assistance with patients and controls recruitment.

7. References

Agachan, B., Yilmaz, H., Karaali, Z. and Isbir, T. (2004). Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus. *Cell. Biochem. Funct.* Vol.22, pp.163–168.

Appel, L., Moore, T., Obarzanek, E., Vollmer, W., Svetkey, L., Sacks, F., Bray, G.A., Vogt, T.M., Cutler, J.A., Windhauser, M.M., Lin, P.H., Karanja, N.A. (1997). Clinical trial of the effects of dietary patterns on blood pressure. *N Engl J Med.* Vol.336, pp.1117-24.

Appel, L.J., Miller, E.R., Jee, S.H., Stolzenberg-Solomon, R., Lin, P.H., Erlinger, T. (2000). Effect of dietary patterns on serum homocysteine: results of a randomized, controlled feeding study. *Circulation.* Vol.102, pp. 852-7.

Arnesen, E., Refsum, H., Bonaa, K.H., Ueland, P.M., Forde, O.H., Nordrehaug, J.E. (1995). Serum total homocysteine and coronary heart disease. *Int. J. Epidemiol.* vol.24, pp.704–709.

Arrol, S., Mackness, M. I. and Durrington, P. N. (2000). Vitamin E supplementation increases the resistance of both LDL and HDL to oxidation and increases cholesteryl ester transfer activity. *Atherosclerosis.* Vol.150, pp.129-134.

Ascherio, A., Rimm, E.B., Giovannucci, E.L. (1992). A prospective study of nutritional factors and hypertension among US men. *Circulation,* vol.86, pp. 475-84.

Aviram, M., Rosenblat, M., Billecke, S. (1999). Human serum paraoxonase (PON1) is inactivated by oxidised low density lipoprotein and preserved by antioxidants. *Free Radicals Biol. Med.* Vol.26, pp.892–904.

Baynes JW, Thorpe SR. (1999). Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. *Diabetes,* vol.48, pp.1-9.

Berstad, P., Konstantinova, S.V., Refsum, H., Nurk, E., Vollset, S.E, Tell, G.S., Ueland, P.M, Drevon, C.A, Ursin, G. (2007).Dietary fat and plasma total homocysteine concentrations in 2 adult age groups: the nordland Homocysteine Study. *Am. J. Clin. Nutr.* Vol.85, pp.1598–1605.

Blatter, M.C., James, R. W., Messmer, S., Barja, F. and Pometta, D. (1993). Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. *Eur. J. Biochem.* Vol. 211, pp. 871-879

Boemi, M., Leviev, I., Sirolla, C., Pieri, C., Marra, M. and James, R. W. (2001). Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. *Atherosclerosis.* Vol.155, pp.229-35.

Bostom, A.G., Silberhatz, H., Rosenberg, I.H., Selhub, J., D’Agostino, R.B., Wolf, P.A. (1999). Non-fasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. *Arch Intern Med.* Vol.159, pp.1077-80.
Boushey, C.J., Beresford, S.A., Omenn, G.S. and Motulsky, A.G. (1995). A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J. Am. Med. Assoc. vol.274, pp. 1049–1057.

Castro, R., Rivera I, Blom, H.J., Jakobs, C., Tavares de Almeida, I. (2006). Homocysteine metabolism, hyperhomocystenemia and vascular disease: an overview. J Inherit Metab Dis, vol.29, pp.3-20.

Castro, R., Rivera, I., Blom, H.J., Jakobs, C., Tavares de Almeida, I. (2006). Homocysteine metabolism, hyperhomocystenemia and vascular disease: an overview. J Inherit Metab Dis. Vol.29, pp.3-20.

Dardik, R., Varon, D., Tamarin, I., Zivelin, A., Salomon, O., Shenkman, B. (2000). Homocysteine and oxidized low density lipoprotein enhanced platelet adhesion to endothelial cells under flow conditions: distinct mechanisms of thrombogenic modulation. Thromb Haemost. Vol.83, pp.338-44.

Deakin, S., Leviev, I., Gomaraschi, M., Calabresi, L., Franceschini, G. and James, R. W. (2002). Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J. Biol. Chem. Vol.277, pp.4301–4308.

Diakoumopoulou, E., Tentolouris, N., Kirlaki, E., Perrea, D., Kitsou, E., Psallas, M., Doulgerakis, D., Katsilambros N. (2005). Plasma homocysteine levels in patients with type 2 diabetes in a Mediterranean population: relation with nutritional and other factors. Nutr Metab Cardiovasc Dis. Vol.15, n.(2), pp.109-17.

Erl, W., Weber, P.C., Weber, C. (1998). Monocytic cell adhesion to endothelial cells stimulated by oxidized low density lipoprotein is mediated by distinct endothelial ligands. Atherosclerosis. Vol.136, pp.297-303.

Ferguson, E., Hogg, N., Antholine, W.E., Joseph, J., Singh, R.J., Parthasarathy, S. (1999). Characterization of the adduct formed from the reaction between homocysteine thiolactone and low-density lipoprotein: antioxidant implications. Free Radic Biol Med. Vol.26, pp. 968-77.

Ferretti, G., Bacchetti, T., Marchioni, C., Caldarelli, L. and Curatola, G. (2001). Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol. Vol.38, pp.163–169.

Frosst, P., Blom, H.J., Milos, R., Goyette, P., Sheppard, C.A., Matthews, R.G. (1995). A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. Vol.10, pp.111-3.

Fryer, R.H., Wilson, B.D., Gubler, D.B., Fitzgerald, L.A., Rodgers, G.M. (1993). Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler. Thromb. Vol.13, pp.1327–1333.

Furlong, C.E., Richter, R.J., Seidel, S.L., Motulsky, A.G. (1988). Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet. Vol.43, pp.230–8.

Genest, J.J. Jr, McNamara, J.R., Salem, D.N., Wilson, P.W., Schaefer, E.J., Malinow, M.R. (1990). Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol. Vol.16, pp.1114-9.
Gouedard, C., Barouki, R. and Morel, Y. (2004). Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependant mechanism. *Mol. Cell. Biol.*, Vol.24, pp.5209–5222.

Graham, I.M., Daly, L.E., Refsum, H.M., Robinson, K., Brattstrom, L.E., Ueland, P.M. (1997). Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. *J Am Med Assoc.* vol.277, n.(22), pp. 1775-81.

Hackam, D.G., Anand, S.S. (2003). Emerging risk factors for atherosclerotic vascular disease. *J Am Med Assoc.* vol.290, pp.932-40.

Harker, L.A., Harlan, J.M., Ross, R. (1983). Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. *Circ. Res.* Vol.53, pp.731–739.

Hayek, T., Fuhrman, B., Vaya, J. et al. (1997). Reduced progression of atherosclerosis in the apolipoprotein E deficient mice following consumption of red wine, or its polyphenols quercetin, or catechin, is associated with reduced susceptibility of LDL to oxidation and to aggregation. *Arterioscler., Thromb., Vasc. Biol.* Vol.17, pp.2744–2752.

Hedrick, C. C., Thorpe, S. R., Fu, M. X. et al. (2000). Glycation impairs high-density lipoprotein function. *Diabetologia*. Vol.43, pp.312-320.

Holvoet, P., Mertens, A., Verhamme, P. (2001). Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. *Arterioscler Thromb Vasc Biol*. Vol.21, pp.844–8.

Jacobsen, D.W. (2001) in Homocysteine in Health and Disease (Carmel, R. and Jacobsen, D.W., eds), pp. 425–440, Cambridge University Press, Cambridge

Jakubowski, H. (1997). Metabolism of homocysteine thiolactone in human cell cultures. *J Biol Chem*. vol. 272, pp.1935-42.

Jakubowski, H. (2000). Homocysteine thiolactone: metabolic origin and protein homocysteinylilation in humans. *J Nutr.* Vol.130, pp.377-81.

Jakubowski, H. (2004). Biochemical basis of homocysteine toxicity in humans. *Mol Cell Life Sci.* vol.61, pp.470–87. Jakubowski, H. (1999). Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. *FASEB J.* vol.13, pp.2277–83.

Jakubowski, H. (2006). Pathophysiological consequences of homocysteine excess. *J Nutr.* Vol.136, pp.1741-9.

Jarvik, G. P., Tsai, N. T., McKinstry, L. A. (2002). Vitamin C and E intake is associated with increased paraoxonase activity. *Arterioscler., Thromb., Vasc. Biol.* Vol.22, pp.1329–1333.

Kang, S.S., Wong, P.W., Malinow, M.R. (1992). Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. *Annu. Rev. Nutr.* vol.12, pp.279–298.

Kannel, WB., McGee, DL. (1979). Diabetes and cardiovascular disease. The Framingham study. *JAMA.* Vol.241, pp.2035–2038.

Kaplan, M., Hayek, T., Raz, A. et al. (2001). Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. *J Nutr.* Vol.131, pp.2082–2089.

Kloor, D., Osswald, H. (2004) S-Adenosylhomocysteine hydrolase as a target for intracellular adenosine action. *Trends Pharmacol. Sci.* vol.25, pp. 294–297.
Interactions Between Total Plasma Homocysteine, Oxidized LDL Levels, Thiolactonase Activities and Dietary Habits in Tunisian Diabetic Patients

Kordonouri, O., James, R. W., Bennetts, B. (2001). Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. *Metab. Clin. Exp.* Vol.50, pp. 657–660.

Koubaa, N., Hammami, S., Nakbi, A., Ben Hamda, K., Mahjoub, S., Kosaka, T. Hammami, M. (2008). Relationship between thiolactonase activity and hyperhomocysteinemia according to MTHFR gene polymorphism in Tunisian Behcet’s disease patients. *Clin Chem Lab Med.* Vol. 46, n(2), pp.187–192.

Koubaa, N., Nakbi, A., Smaoui, M., Abid, N., Chaaba, R., Abid, M., Hammami, M. (2007). Hyperhomocysteinemia and elevated ox-LDL in Tunisian type 2 diabetic patients: Role of genetic and dietary factors. *Clin Biochem.* Vol.46, n.(2), pp.187–192.

Kushi, L.H., Lenart, E.B ., Willett, W.C. (1995). Health implications of Mediterranean diets in light of contemporary knowledge. 1. Plant foods and dairy products. *Am J Clin Nutr.* Vol.61(suppl), pp.1407–15.

Lanfredini, M., Fiorina, P., Peca, M.G., Veronelli, A., Mello, A., Astorri, E., Dall’Aglio, P., Craveri, A. (1998). Fasting and post-methionine load homocyst(e)ine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin-dependent diabetes mellitus patients. *Metabolism.* Vol.47, pp.915-21.

Letellier, C., Durou, M. R., Jouanolle, A. M., Le Gall, J. Y., Poirier, J. Y. and Ruelland, A. (2002). Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications. *Diabetes Metab.* Vol.28, pp. 297–304.

Leviev, I., Kalix, B., Brulhart Meynet, M.-C. and James, R. W. (2001). The paraoxonase PON1 promoter polymorphism C(−107)T is associated with increased serum glucose concentrations in non-diabetic patients. *Diabetologia.* Vol. 44, pp.1177–1183.

Lutsey, P.L., Steffen, L.M., Feldman, H.A., Hoelscher, D.H., Webber, L.S., Luepker, R.V. (2006). Serum homocysteine is related to food intake in adolescents: the Child and Adolescent Trial for Cardiovascular Health. *Am J Clin Nutr.* Vol.83, pp.1380-6.

Mackness, B., Durrington, P. N., Boulton, A. J., Hine, D. and Mackness, M. I. (2002). Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. *Eur. J. Clin. Invest.* Vol.32, pp. 259–256.

Mackness, B., Mackness, M. I., Arrol, S. et al. (1998) Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. *Atherosclerosis.* Vol.139, pp. 341–349.

Majors, A., Ehrhart, L.A., Pezacka, E.H. (1997). Homocysteine as a risk factor for vascular disease, enhanced collagen production and accumulation by smooth muscle cells. *Arterioscler Thromb Vasc Biol.* Vol.17, pp.2074–81.

Mansoor, M.A., Bergmark, C., Haswell, S.J., Savage, I.F., Evans, P.H., Berge, R.K. (2000). Correlation between plasma total homocysteine and copper in patients with peripheral vascular disease. *Clin Chem.* Vol.46, pp.385-91.

Mansoor, M.A., Ueland, P.M., Aarsland, A., Svardal, A.M. (1993). Redox status and protein binding of plasma homocysteine and other aminothiols in patients with homocystinuria. *Metabolism.* Vol. 42, pp.1481-5.

Matteucci, E., Rossi, L., Mariani, S., Fagnani, F., Quilici, V., Cinapri, V. (2002). Blood levels of total homocysteine in patients with type 1 diabetes (with no complications, diabetic
nephropathy and/or retinopathy) and in their non-diabetic relatives. *Nutr Metab Cardiovasc Dis.* Vol.12, pp. 184-9.

Mooradian, A.D. (1991). Increased serum conjugated dienes in elderly diabetic patients. *J Am Geriatr Soc.* Vol. 39, pp.571-5.

Naruszewicz, M., Mirkiewicz, E., Olszewski, A.J. and McCully, K.S. (1994). *Nutr. Metab. Cardiovasc. Dis.* Vol.4, pp.70-77.

Nishinaga, M., Ozawa, T. and Shimada, K. (1993). Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. *J Clin Invest.* vol.92, pp.1381–1386.

Nishio, E., Watanabe Y. Br. (1997). Oxidized LDL induces apoptosis in cultured smooth muscle cells: a possible role for 7-ketocholesterol. *J Pharmcol.* Vol.122, pp.269–274.

Nygaard, O., Refsum, H., Ueland, P.M., Vollset, S.E. (1998). Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. *Am J Clin Nutr.* Vol.67, pp.263-70.

Parthasarathy, S., Santanam, N., Auge, N. (1998). Oxidised low-density lipoprotein: a two-faced Janus in coronary artery disease? *Biochem Pharmacol.* Vol.56, pp.279–284.

Passaro, A., D’Ellia, K., Pareschi, P.L., Calzoni, F., Carantonii, M., Fellin, R. (2000). Factors influencing plasma homocysteine levels in type 2 diabetes. *Diabetes Care.* Vol.23, pp.420-1.

Pavia, C., Ferrer, I., Valls, C., Artuch, R., Colome, C., Vilaseca, M.A. (2000). Total homocysteine in patients with type 1 diabetes. *Diabetes Care.* Vol.23, pp.84-7.

Perna, A.F., Ingrosso, D., Lombardi, C., Acanfora, F., Satta, E., Cesare, C.M. (2003). Possible mechanisms of homocysteine toxicity. *Kidney Int Suppl.* Vol.84, pp.137-40.

Price, J.F., Fowkes, F.G.R. (1997). Antioxidant vitamins in the prevention of cardiovascular disease. *Eur Heart J.* Vol.18, pp.719-27.

Ratnoff, O.D. (1968). Activation of Hageman factor by L-homocystine. *Science.* Vol.162, pp.1007–1009.

Refsum, H., Nurk, E., Smith, A.D., Ueland, P.M., Gjesdal, C.G., Bjelland, I., Tverdal, A., Tell, G.S., Nygard, O., Vollset, S.E. (2006).The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. *J Nutr.* Vol.136, pp. 1731–1740.

Rocchi, E., Bursi, F., Ventura, P., Ronzoni, A., Gozzi, C., Casalgrandi, G. (2007). Anti- and pro-oxidant factors and endothelial dysfunction in chronic cigarette smokers with coronary heart disease. *Eur J Intern Med.* Vol.18, pp.314-20.

Salardi, S., Cacciari, E., Sassi, S., Grossi, G., Mainetti, B., Dalla Casa, C. (2000). Homocysteinemia, serum folate and vitaminB12 in very young patients with diabetes mellitus type 1. *J Pediatr Endocrinol Metab.* Vol.13, pp.1621-7.

Shih, D.M., Gu, L., Xia, Y.R., Navab, M., Li, W.F., Hama, S. (1998). Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. *Nature.* Vol.394, pp.284-7.

Smaoui, M., Koubaa, N., Hammami, S., Abid, N., Feki, M., Chaaba, R., Attia, N., Abid, M., Hammami, M. (2006). Association between dietary fat and antioxidant status of Tunisian type 2 diabetic patients. *Prostaglandins, Leukot Essent Fat Acids.* Vol.74, pp.323-9.
Sniderman, A.D., Pedersen, T., Kjekshus, J. (1997). Putting low-density lipoproteins at center stage in atherogenesis. *Am J Cardiol*. Vol.79, n.(1), pp.64-67.

Stampfer, M.J., Malinow, M.R., Willett, W.C., Newcomer, L.M., Upson, B., Ullmann, D., Tishler, P.V, Hennekens, C.H. (1992). A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. *J. Am. Med. Assoc.* vol. 268 pp. 877–881.

Steinberg, D., Witztum, J.L. (2002). Is the oxidative modifications hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date reflect the hypothesis?. *Circulation*. Vol.105, pp.2107–2111.

Sutherland, W., Walker, R. J., de Jong, S. A., van Rij, A. M., Phillips, V. and Walker, H. L. (1999). Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. *Arterioscler., Thromb., Vasc. Biol.* Vol.19, pp.1340–1347.

Tomas, M., Senti, M., Eluosa, R. (2001). Interaction between the Gln-Arg 192 variants of the paraoxonase gene and oleic acid intake as a determinant of high density lipoprotein cholesterol and paraoxonase activity. *Eur. J. Pharmacol.* Vol.432, pp.121–128.

Toshima, S., Hasegawa, A., Kurabayashi, M. (2000). Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. *Arterioscler. Thromb. Vasc. Biol.* Vol.20, pp.2243–7.

Tsai, J.C., Perrella, M.A., Yoshizumi, M., Hsieh, C.M., Haber, E., Schlegel, R., Lee, M.E. (1994). Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. *Proc. Natl. Acad. Sci. U.S.A.* vol.91, pp.6369–6373.

Tsai, M., Garg, U., Key, N.S. (1996). Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria. *Atherosclerosis*. Vol.172, pp.69–77.

Upchurch, Jr, G.R., Welch, G.N., Fabian, A.J., Freedman, J.E., Johnson, J.L., Keaney, Jr, J.F. and Loscalzo, J. (1997). Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. *J. Biol. Chem.* Vol.272, pp.17012–17017.

Vadachkoria, S., Sanchez, S.E., Qiu, C., Muy-Rivera, M., Malinow, M.R., Williams, M.A. (2004). Hyperhomocyst(e)inemia and elevated soluble vascular cell adhesion molecule-1 concentrations are associated with an increased risk of preeclampsia. *Gynecol Obstet Invest*. Vol.58, pp.133-9.

Velazquez, E., Winocour, P.H., Kesteven, P., Alberti, K.G., Laker, M.F. (1991). Relation of lipid peroxides to macrovascular disease in type 2 diabetes. *Diabet Med.* Vol.88, pp.752–8.

Wald D.S., Law, M, Morris JK (2004). The dose-response relation between serum homocysteine and cardiovascular disease: implications for treatment and screening. *Eur J Cardiovasc Prev Rehabil*. Vol.11, pp.250-3.

Wald D.S., Law, M., Morris, J.K. (2002). Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. *BMJ*. Vol.325, pp.1202.

Wald, D.S., Law, M., Morris, J.K. (2002). Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. *BMJ*. Vol.325, pp.1202.

Wallace, A. J., Sutherland, W. H., Mann, J. I. and Williams, S. M. (2001). The effect of meals rich in thermally stressed olive and safflower oils on postprandial serum paraoxonase activity in patients with diabetes. *Eur. J. Clin. Nutr.* Vol.55, pp.951-958.
Welch, G.N. Loscalzo, J. (1998). Homocysteine and atherothrombosis. *N. Engl. J. Med.* Vol.338, pp.1042-1050.

Wollesen, F., Brattsrom, L., Refsum, H., Ueland, P.M., Berglund, L., Berne, C. (1999). Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. *Kidney Int.* vol.55, pp.1028-35.

Yeromenko, Y., Lavie, L., Levy, Y. (2000). Homocysteine and cardiovascular risk in patients with diabetes mellitus. *Nutr Metab Cardiovasc Dis.* Vol.11, pp.108-16.
Adipocytes are important in the body for maintaining proper energy balance by storing excess energy as triglycerides. However, efforts of the last decade have identified several molecules that are secreted from adipocytes, such as leptin, which are involved in signaling between tissues and organs. These adipokines are important in overall regulation of energy metabolism and can regulate body composition as well as glucose homeostasis. Excess lipid storage in tissues other than adipose can result in development of diabetes and nonalcoholic fatty liver disease (NAFLD). In this book we review the role of adipocytes in development of insulin resistance, type 2 diabetes and NAFLD. Because type 2 diabetes has been suggested to be a disease of inflammation we included several chapters on the mechanism of inflammation modulating organ injury. Finally, we conclude with a review on exercise and nutrient regulation for the treatment of type 2 diabetes and its co-morbidities.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Nadia Koubaa, Maha Smaoui, Sounira Mehri, Amel Nakbi, Sonia Hammami, Raja Chaaba, Khalidoun Ben Hamda, Fethi Betbout, Mohamed Ameur Frih and Mohamed Hammami (2011). Interactions Between Total Plasma Homocysteine, Oxidized LDL Levels, Thiolactonase Activities and Dietary Habits in Tunisian Diabetic Patients, Role of the Adipocyte in Development of Type 2 Diabetes, Dr. Colleen Croniger (Ed.), ISBN: 978-953-307-598-3, InTech, Available from: http://www.intechopen.com/books/role-of-the-adipocyte-in-development-of-type-2-diabetes/interactions-between-total-plasma-homocysteine-oxidized-ldl-levels-thiolactonase-activities-and-diet
